Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have unveiled a novel diagnostic platform that integrates three-dimensional bioprinting, artificial intelligence, and label-free high-speed imaging to accelerate cancer therapy discovery and enable personalized treatment screening. Published in Nature Protocols in 2026, the technology addresses longstanding limitations in tumor modeling by generating patient-derived cancer organoids at scale while continuously monitoring their biological response to pharmaceutical interventions. The platform utilizes extrusion bioprinting to construct three-dimensional tumor organoids embedded within extracellular matrix scaffolds optimized for high-throughput multiwell assays. Rather than relying on conventional fluorescent dyes or endpoint assays that alter cellular behavior, the system employs quantitative phase imaging to track biomass accumulation and growth dynamics in real time. This non-invasive approach preserves native cell physiology and enables longitudinal observation of tumor fitness across extended treatment periods. To process the resulting imaging datasets, the workflow incorporates automated image reconstruction, deep learning-based cellular segmentation, and machine learning algorithms that track individual organoid responses to therapeutic agents. This architecture allows researchers to quantify drug efficacy at single-organoid resolution across thousands of samples, capturing tumor heterogeneity and identifying rare resistant subpopulations that average bulk assays typically obscure. Dr. Michael Teitell, director of the UCLA Health Jonsson Comprehensive Cancer Center and co-senior author of the study, emphasized the platform capacity to shift cancer drug screening from population-level averages to precise, individualized response mapping. By determining which specific organoids thrive or decline under therapeutic pressure, the system reveals underlying mechanisms of drug sensitivity and resistance. This granular tracking capability enables the simultaneous evaluation of hundreds of potential compounds, significantly compressing the timeline for preclinical drug validation. The technology establishes a viable pathway for precision oncology, allowing clinicians to test multiple drug regimens against a patient specific tumor cells prior to initiating clinical treatment. This ex vivo screening capability is particularly valuable for rare malignancies and patients with limited therapeutic options, where traditional treatment protocols often yield suboptimal outcomes. By bridging high-throughput computational analysis with biologically faithful tumor modeling, the UCLA research team has engineered a scalable infrastructure that aligns laboratory drug discovery with clinical decision-making. The system standardized workflow and non-destructive monitoring protocols position it for broader adoption in academic research and pharmaceutical development pipelines, ultimately advancing the trajectory toward patient-specific cancer therapies.